Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

BACKGROUND: Early reduction in albuminuria with an SGLT2 (sodium‐glucose cotransporter 2) inhibitor may be a positive indicator of long‐term cardiovascular and renal benefits. We assessed changes in albuminuria during the first 12 weeks of treatment and subsequent long‐term cardiovascular and renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Waijer, Simke W., Xie, Di, Inzucchi, Silvio E., Zinman, Bernard, Koitka‐Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximillian, Inker, Lesley A., Wanner, Christoph, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727012/
https://www.ncbi.nlm.nih.gov/pubmed/32893717
http://dx.doi.org/10.1161/JAHA.120.016976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727012/
https://www.ncbi.nlm.nih.gov/pubmed/32893717
http://dx.doi.org/10.1161/JAHA.120.016976

Ejemplares similares